Is Intuitive Surgical a Buy After Its Latest Earnings Report?
At first glance, its numbers were impressive.
At first glance, its numbers were impressive.
Shares of Intuitive Surgical are down nearly 40% this year.
Andra AP fonden grew its position in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 139.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 50,050 shares of the medical equipment provider's stock after purchasing an additional 29,168 shares during the period.
AlTi Global Inc. grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 353.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,023 shares of the medical equipment provider's stock after purchasing an additional 2,356 shares during the quarter.
Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.
Intuitive Surgical (ISRG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical, Inc. has declined ~38% since my previous Hold, driven by valuation concerns and recent structural headwinds. Despite ISRG's Q2 2026 earnings growth, margin expansion, and raised guidance, markets reacted to a slowdown in U.S. procedure growth. Pressures stem from expiring ACA subsidies impacting elective surgeries and weight loss drugs reducing bariatric procedure demand.
Intuitive Surgical posted strong sales and profit gains in the second quarter. But management issued a tepid forecast for the rest of 2026.
Intuitive Surgical TodayISRGIntuitive Surgical$345.42 -56.91 (-14.15%) As of 07/17/2026 04:00 PM Eastern52-Week Range$344.55▼$603.88P/E Ratio39.57Price Target$523.46Add to WatchlistIntuitive Surgical NASDAQ: ISRG was part of the artificial intelligence (AI)/robotics trade before it became mainstream.
Intuitive Surgical (NASDAQ: ISRG) reported a solid second quarter of 2026, with management pointing to continued global adoption of its da Vinci, da Vinci SP and Ion platforms, even as U.S. procedure growth moderated and China remained challenging. Chief Executive Officer Dave Rosa said total procedures increased 16% in the quarter, driven by 15% growth in
Intuitive Surgical remains a buy despite a nearly 30% stock decline and post-earnings volatility. Adoption metrics are resilient, with strong system placements and installed base growth offsetting softer U.S. procedure growth. Profitability improved: Q2 non-GAAP gross margin expanded to 70%, operating margin to 42.1%, and EPS beat by $0.30.
Allspring Global Investments Holdings LLC lowered its holdings in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 5.7% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 137,212 shares of the medical equipment provider's stock after selling 8,356 shares during the period. Allspring
Intuitive Surgical, Inc. remains a compelling long-term compounder, with operational improvements and robust growth prospects despite recent market headwinds. ISRG delivered solid Q2 results: revenue and EPS beat estimates, da Vinci procedures grew 20%, and gross margin reached 70%, reinforcing ISRG's strong positioning. Current valuation near a 5-year low—~35x forward earnings—offers a more attractive entry point, with multiple compression creating a margin of safety.
Intuitive Surgical (ISRG) shares plummeted Friday after the maker of robotic surgical tools failed to raise the outlook for its flagship product despite better-than-expected second-quarter results.
ISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.
Intuitive Surgical Inc. (NASDAQ:ISRG) stock fell sharply Friday after the company reaffirmed its 2026 da Vinci procedure growth outlook but flagged slowing U.S. procedure trends and insurance-related headwinds that weighed on investor sentiment.
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
Intuitive Surgical (NASDAQ: ISRG) shares fell about 11% on Friday after the robotic surgery company reported second-quarter results that topped Wall Street expectations but disappointed investors with slower US procedure growth and a cautious full-year outlook. The company reported second quarter revenue of $2.89 billion, up 19% from a year earlier and above analysts' consensus estimate of $2.82 billion.
Diane King Hall discusses Intuitive Surgical (ISRG) earnings, explaining how GLP-1 trends have hit the company. She also talks about SpaceX (SPCX) shares coming back to Earth after scrubbing Starship's test flight, and HSBC's upgrade on Apple (AAPL) to buy from hold.